BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.
52 Week High
52 Week Low
Data Provided by Refinitiv. Minimum 15 minutes delayed.
More information is coming soon.
Recent BDSI News
BioDelivery Sciences Reports Second Quarter 2021 Results
August 4, 2021
Total Company Net Revenue of $41.4 Million Driven by BELBUCA ® All-Time High TRx Market Share Strong Profitability with GAAP Net Income of $9.1 Million , or $0.09 per share, EBITDA Margin of 32%, and Non-GAAP Net Income of $12.5 Million , or $0.12 per Share, Drives Operating Cash Generation of $9.2 ...
BioDelivery Sciences Announces Agreement to Acquire U.S. and Canadian Rights to FDA-approved ELYXYB™ for the Acute Treatment of Migraine
August 4, 2021
The only FDA-approved, ready-to-use oral solution for the acute treatment of migraine with or without aura in adults First step to building a growth platform in Neurology Patent protection until 2036 RALEIGH, N.C. , Aug. 04, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , ...
BioDelivery Sciences to Report Second Quarter 2021 Financial Results on August 4, 2021
July 22, 2021
RALEIGH, N.C. , July 22, 2021 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its second quarter 2021 ...